Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ligand Pharmaceuticals (LGND) FCF Margin (2016 - 2025)

Ligand Pharmaceuticals' FCF Margin history spans 16 years, with the latest figure at 76.95% for Q4 2025.

  • For Q4 2025, FCF Margin rose 1045.0% year-over-year to 76.95%; the TTM value through Dec 2025 reached 7.64%, down 556.0%, while the annual FY2025 figure was 18.41%, 522.0% up from the prior year.
  • FCF Margin for Q4 2025 was 76.95% at Ligand Pharmaceuticals, up from 56.13% in the prior quarter.
  • Across five years, FCF Margin topped out at 135.38% in Q1 2022 and bottomed at 73.26% in Q3 2024.
  • The 5-year median for FCF Margin is 29.02% (2023), against an average of 36.18%.
  • The largest annual shift saw FCF Margin skyrocketed 11249bps in 2022 before it crashed -11659bps in 2025.
  • A 5-year view of FCF Margin shows it stood at 57.87% in 2021, then soared by 88bps to 108.7% in 2022, then tumbled by -75bps to 27.22% in 2023, then skyrocketed by 144bps to 66.5% in 2024, then grew by 16bps to 76.95% in 2025.
  • Per Business Quant, the three most recent readings for LGND's FCF Margin are 76.95% (Q4 2025), 56.13% (Q1 2025), and 66.5% (Q4 2024).